Pharmacologic treatment of type 2 diabetes: oral medications. - Wikidata - wikimedia - TriplyDB

Pharmacologic treatment of type 2 diabetes: oral medications.

Pharmacologic treatment of type 2 diabetes: oral medications.

http://www.wikidata.org/entity/Q38350347

about

The Effect of Diabetes Mellitus on Apoptosis in Hippocampus: Cellular and Molecular Aspects Neuregulin 1 Improves Glucose Tolerance in db/db Mice Metformin and Resveratrol Inhibited High Glucose-Induced Metabolic Memory of Endothelial Senescence through SIRT1/p300/p53/p21 Pathway Metformin inhibits hepatocellular glucose, lipid and cholesterol biosynthetic pathways by transcriptionally suppressing steroid receptor coactivator 2 (SRC-2).Moieties in antidiabetic drugs as a target of insulin receptors in association with common neurological disorders.Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.Rosemary Extract as a Potential Anti-Hyperglycemic Agent: Current Evidence and Future Perspectives.Insulin resistance, role of metformin and other non-insulin therapies in pediatric type 1 diabetes.Adjunctive metformin for antipsychotic-related hyperprolactinemia: A meta-analysis of randomized controlled trials.Progressing From Metformin to Sulfonylureas or Meglitinides.Exercise after You Eat: Hitting the Postprandial Glucose Target.Effects of Lobeglitazone, a New Thiazolidinedione, on Osteoblastogenesis and Bone Mineral Density in Mice.The prescribing trend of oral antidiabetic agents for type 2 diabetes in Taiwan: An 8-year population-based study.Nischarin inhibition alters energy metabolism by activating AMP-activated protein kinase.

P2860

Q26748541-701B1595-5A0F-4384-BD80-BFEB1692880A Q35730880-6A7BADAB-B8BB-4B35-8891-F104786E644B Q35858703-2527F881-C5BD-442F-8FE2-C9B9CE4AB3B1 Q36262595-6F5AA53C-9580-4F2D-B756-28F3F5EAE408 Q36742174-A665BEF1-3FF9-48AB-9866-0581E7534AEA Q38577303-0E19A232-60A6-47EB-8309-EF04B329261A Q38634459-E2A94799-780E-4C5F-A8BA-CFC155A12C71 Q38642435-4EAC03D5-EFA4-48AC-B0D8-78A98BEA8D47 Q38858121-B8E094BB-0C82-49C9-ADA2-580BDF8D187A Q38952882-A7EEDDB8-0CBF-43A7-AA8D-811AFA2479E1 Q42018024-8CE1C242-5E05-4C92-B1EA-04EEBD8B1CB2 Q42366433-0FFD96A7-2668-47CE-AF85-D44B6BDE0AEA Q47360637-F8CFF829-1710-4F5E-92DF-4E576D5A61A5 Q47904028-AE669C29-7780-4061-B973-9D1F20BA142F

P2860

Pharmacologic treatment of type 2 diabetes: oral medications.

http://www.wikidata.org/entity/Q38350347

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Pharmacologic treatment of type 2 diabetes: oral medications.

@en

type

label

Pharmacologic treatment of type 2 diabetes: oral medications.

@en

prefLabel

Pharmacologic treatment of type 2 diabetes: oral medications.

@en

P1433

Q38350347-D34998E6-D61C-4997-9296-154755675AD9

P1476

Q38350347-2383D968-D6D9-4067-80C5-2117CC150458

P2093

Q38350347-22189078-AE55-4DF4-999A-61A25F17CB82

Q38350347-380B80C9-6045-432A-8823-FE2D9FF1FA8C

Q38350347-58ED117D-E735-4088-97EB-0EDEAE554652

Q38350347-6441DF27-715B-4AA1-A8BF-F618DA8DEADF

Q38350347-6BA6C0CB-83D8-47F7-AD2F-F9F4D6A5EF09

Q38350347-78A3DC89-E155-4238-AAA7-290CF511FAAE

Q38350347-816D9CF0-8D63-4EF2-A8A2-F5B2445A94BD

Q38350347-89B39C9F-0C6A-4B58-876D-8112215FAF59

Q38350347-B499FAFE-B7F8-41DD-AEF2-630BA0B9DE5A

Q38350347-CC19B2A4-3459-4A63-92EE-9A050D461593

P2860

Q38350347-032776F4-D3DB-44AD-A5DC-D96230345D3F

Q38350347-04028EFB-A810-41C5-A135-87A3A777F08F

Q38350347-060DC8AF-6D67-4613-A0CA-3E642CDA8116

Q38350347-07BE54A3-F56F-4AA7-B754-28BBE3EDFB82

Q38350347-082F4992-E4B6-4EF7-930D-C3F38893ABCC

Q38350347-095A76D0-A564-43F1-911B-391E9771AC0D

Q38350347-0A509CDB-D3A0-42BA-94EE-BE5DF74FAA33

Q38350347-0DE4769F-A8E9-474E-87B8-690CB556B745

Q38350347-0E2D3615-10D9-4ED6-BD17-EAE4BC579FAC

Q38350347-111021B9-CA63-4D57-B34C-809858097A6B

P304

Q38350347-8DBB2373-4364-4125-B755-53F820B48A4C

P31

Q38350347-D746E9DE-4E2B-4408-AD67-45C192DC3883

P356

Q38350347-89802FDC-0D10-4043-8023-D1C2CCC6DB42

P407

Q38350347-5D08E055-5FDD-4DD5-9A50-4CFE4F772390

P433

Q38350347-F9B55D94-5A01-4BB9-9A3A-14E211AFB7C6

P478

Q38350347-CC37350F-D4AE-4F8B-9468-F5B5900049F9

P577

Q38350347-36BAE0E5-FEF0-41DC-B1A1-292F8B6B7932

P698

Q38350347-F5537320-42C7-4B77-83FF-554C87C76975

P921

Q38350347-B3C4E58F-5F4A-40DF-8DA5-C9A112C050B7

P356

1060028014558289

P1433

Annals of Pharmacotherapy

P1476

Pharmacologic treatment of type 2 diabetes: oral medications.

@en

P2093

Angela Zielinski

http://www.w3.org/2001/XMLSchema#string

Ann Marie Householder

http://www.w3.org/2001/XMLSchema#string

Arpi H Roach

http://www.w3.org/2001/XMLSchema#string

Emily E Cole

http://www.w3.org/2001/XMLSchema#string

Erin E Thompson

http://www.w3.org/2001/XMLSchema#string

Jennifer A Jende

http://www.w3.org/2001/XMLSchema#string

Linda Tran

http://www.w3.org/2001/XMLSchema#string

Mallory L Accursi

http://www.w3.org/2001/XMLSchema#string

Melinda Amornyard

http://www.w3.org/2001/XMLSchema#string

Shuruq A Atway

http://www.w3.org/2001/XMLSchema#string

P2860

Use of metformin in the setting of mild-to-moderate renal insufficiency

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Risk Factors of Vitamin B12 Deficiency in Patients Receiving Metformin

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial

Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

P304

540-556

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1060028014558289

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25667196

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes